Dyadic International rapidly developed stable C1 cell lines and produced purified Bundibugyo Ebola virus antigens within approximately 15 days, delivering them for preclinical evaluation of a potential non-mRNA vaccine. This rapid production is crucial amid the active Bundibugyo ebolavirus outbreak, which currently lacks approved vaccines or treatments. Dyadic's C1 platform offers a scalable, cost-effective alternative to traditional methods, potentially accelerating vaccine and antibody development during health emergencies. The company aims to expand its platform's adoption and commercial opportunities in biologics manufacturing, supported by collaborations with global health organizations and funding from the Gates Foundation.
The fourth Digital Assets & Tokenization Summit held in Singapore brought together global financial leaders, institutional investors, and tech innovators to discuss how AI, tokenization, and digital assets are transforming capital markets. Key discus...
A London-based novelist, using the pen name A. Nobody, has independently published a thriller titled "A Nobody: London Doesn't Believe in Superheroes." The story follows a masked hero who stops violent crimes in London anonymously, reflecting the aut...
Coastal Community Bank has committed $5 million to the Solomon Hess SBA Loan Fund to support small businesses in Snohomish and King Counties. This investment helps expand access to capital for businesses that may not qualify for traditional loans, fo...
Amphenol reported strong growth in Q2 FY2026, driven primarily by increased demand for AI-related products and the successful integration of its CCS acquisition. The IT Datacom segment, now representing 43% of sales, grew 63% organically year-over-ye...
Equity Bancshares reported Q3 2026 GAAP EPS of $1.29, matching analyst estimates, while its core EPS of $1.40 exceeded expectations by $0.10. The bank continues its strategy of growth through acquisitions, announcing a deal with Lincoln Bancorp, thou...
